ClinicalTrials.gg
Not yet recruitingNCT07828795RCTUpdated Sep 23, 2026

Crochet Octopus in Reducing Procedural Pain During Heel Lance in Preterm Neonates

An interventional study of Crochet Octopus in Preterm Neonates, Heel Lance Procedures and Procedural Pain, sponsored by Mansoura University. Not yet recruiting. Open to participants aged 2 Days to 30 Days. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Mansoura University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
2 Days to 30 Days
Sex
All
01

Study summary

Neonates, particularly those hospitalized in neonatal intensive care units (NICUs), are subjected to numerous painful procedures essential for their diagnosis and monitoring. Heel lance, performed for routine blood sampling, stands as one of the most frequently encountered painful experiences for these vulnerable infants, as robust neurobiological evidence confirms that even preterm infants possess the anatomical and functional capacity to perceive pain, manifesting measurable physiological, hormonal, and behavioral responses. The daily average of acute painful events can reach up to 10-15 procedures in the NICU, and repeated exposure to inadequately managed procedural pain has been associated with immediate physiological instability as well as longer-term alterations in stress regulation, somatosensory processing, and neurodevelopmental outcomes. These vulnerabilities are further compounded in preterm and low birth weight infants who require prolonged hospitalization and specialized care.

Read the detailed description

While pharmacological analgesia is available, its use in neonates is often limited by concerns regarding dosing complexity, potential adverse effects, and safety in this vulnerable population. Consequently, non-pharmacological strategies have become central to neonatal pain management. Interventions such as kangaroo care (skin-to-skin contact), facilitated tucking, breastfeeding, sweet solutions, non-nutritive sucking, and various forms of auditory and tactile stimulation have consistently demonstrated effectiveness in reducing both behavioral and physiological indicators of pain. Breastfeeding has also been identified as the most effective method to reduce pain during heel lance in term newborns. Moreover, auditory interventions such as white noise and mother-sung lullabies have been shown to significantly reduce neonatal pain scores. These findings underscore the growing evidence base supporting non-pharmacological approaches.

garnered attention as a simple, low-cost, and potentially effective tool for neonatal pain management. The crochet octopus is a soft, handmade toy with long, curled tendrils that neonates can grasp, providing tactile stimulation theorized to operate via the gate control theory of pain, whereby non-painful tactile input can close the "gates" to painful signals in the spinal cord. A seminal randomized controlled study by Çövener Özçelik et al. (2023), conducted with 100 term neonates, demonstrated that infants who touched a crochet octopus during heel lance had significantly higher oxygen saturation levels, shorter crying durations, and lower pain scores compared to the control group. More recently, Reddy et al. (2025) confirmed these findings in a randomized controlled trial involving 100 neonates, showing that octopus therapy significantly reduced pain scores, stabilized physiological parameters, and decreased crying duration during minor procedures. The intervention, where the octopus is provided 10 minutes before the procedure, has been shown to affect physiological measurements positively and reduce procedural pain.

02

Conditions studied

  • Preterm Neonates
  • Heel Lance Procedures
  • Procedural Pain

Browse trials for

Keywords

  • Crochet Octopus
  • Procedural Pain
  • Heel Lance
  • Preterm Neonates
03

In context

Pain, Procedural

241 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.

This study's planned enrollment of 98 is close to the median of 90 across 227 interventional studies indexed under Pain, Procedural.

Browse Pain, Procedural studies →

Lead sponsor

Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Days to 30 Days
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Preterm neonates: Gestational age 32-37 weeks
  • Age: 2-30 days postnatal
  • Clinically stable
  • Requiring heel lance for routine blood sampling Exclusion Criteria
  • Major congenital anomalies
  • Neurological disorders
  • Received pharmacological analgesia within 24 hours prior to the procedure
  • Receiving mechanical ventilation or continuous positive airway pressure (CPAP)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Intervention Group (Crochet Octopus)

    Intervention Group (Crochet Octopus)

    Device: Crochet Octopus

  • No intervention
    Control Group (Standard Care)

    Control Group (Standard Care)

Interventions

  • DeviceCrochet Octopus

    1. A standard crochet octopus will be placed with the neonate 10 minutes before the heel lance procedure. 2. The octopus will be positioned so that the neonate can touch its tendrils. 3. The octopus will remain with the neonate during the heel lance procedure. 4. The octopus will remain with the neonate for 10 minutes after the procedure completion. 5. Standard nursing care will be provided as per unit protocol. Crochet Octopus Specifications: * Handmade using 100% cotton yarn * Soft, with 8 curled tendrils approximately 15-20 cm in length * Hypoallergenic materials * Washable and sterilizable * Standard design consistent with published protocols

06

What researchers measure

Primary outcomes

  1. Neonatal Pain

    The Premature Infant Pain Profile (PIPP) will be used to assess pain in preterm neonates (gestational age 32-36 weeks).

    Time frame: through study completion, an average of 3 months

  2. Behavioral State

    The Brazelton Neonatal Behavioral Assessment Scale (NBAS) state categories will be used to classify the neonate's behavioral state

    Time frame: through study completion, an average of 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Karga Yilmaz T, Yavuz B. Comparison of different methods for reducing pain during a heel lance in newborns: a randomized trial. Ital J Pediatr. 2025 Mar 12;51(1):73. doi: 10.1186/s13052-025-01916-w. PubMed 40075464 ↗
  • Covener Ozcelik C, Eren O, Sabaz N, Bulut M. Effect of using crochet octopus in reducing the pain: a randomized controlled study. J Trop Pediatr. 2022 Dec 5;69(1):fmac107. doi: 10.1093/tropej/fmac107. PubMed 36525534 ↗
  • Bastons-Compta A, Astals M, Sanchez E, Garcia-Algar O. Knitted octopuses inside the incubators, a non-evidence based viral practice. Early Hum Dev. 2019 Jan;128:101. doi: 10.1016/j.earlhumdev.2017.09.001. Epub 2017 Sep 8. No abstract available. PubMed 28890146 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared publicly because the dataset contains potentially identifiable participant information. Sharing the raw data could compromise participants' privacy and confidentiality. Therefore, IPD will not be made publicly available. However, anonymized or aggregated data may be considered for sharing upon reasonable request, subject to ethical approval, institutional policies, and applicable data-protection regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.

Of 141 non-industry interventional studies with no phase under Pain, Procedural, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 4 months is below that.

Counting every sponsor, half of 141 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Sep 18, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07828795
Responsible party
Sara Mustafa Hamza Taha (Lecture of Pediatric Nursing, Pediatric Nursing Department, Faculty of Nursing, Mansoura University, Mansoura University) — Principal investigator
First posted
Sep 18, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

Sara Mustafa Hamza Taha, PhD
Contact
sarahamza@mans.edu.eg
+20 01098022749

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion